fitforthem
about

scope and guide to the platform

—research groups

research groups network graph visualization

—repositories

catalog of the institutional repositories

—heritage

selection of collections, museum, cultural sites and ancient books

By continuing your visit to this site, you accept the use of essential cookies.

Read more
6533b821fe1ef96bd127adcf

RESEARCH PRODUCT

C1-02: Randomized Phase II study of vandetanib alone or in combination with carboplatin and paclitaxel as 1st-line treatment for advanced NSCLC

John V. HeymachLuis Paz-aresBruce E. JohnsonMartin SebastianWilfried EberhardtDavid J. StewartPeter LangmuirFilippo De BraudRoy S. HerbstAnnetta D. Krebs

subject

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industryPhases of clinical researchVandetanibCarboplatinchemistry.chemical_compoundOncologyPaclitaxelchemistryInternal medicinemedicineLine (text file)businessmedicine.drug
yearjournalcountryeditionlanguage
2007-08-01Journal of Thoracic Oncology
https://doi.org/10.1097/01.jto.0000283189.62415.3d
EU flag

FORTHEM European University Alliance is co-funded by the European Union. FIT FORTHEM has received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No. 101017248. The content of this website represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission.

University of Jyväskylä logoUniversity of Jyväskylä's websiteUniversity of Burgundy logoUniversity of Burgundy's websiteUniversity of Mainz logoUniversity of Mainz's websiteUniversity of Palermo logoUniversity of Palermo's websiteUniversity of Latvia logoUniversity of Latvia's website
University of Agder logoUniversity of Agder's websiteUniversity of Opole logoUniversity of Opole's websiteUniversity of Sibiu logoUniversity of Sibiu's websiteUniversity of València logoUniversity of València's website
FORTHEM logoFORTHEM alliance's website